Mueller Julius, Miedtke Valentin, Kuellmer Armin, Schiemer Moritz, Bettinger Dominik, Thimme Robert, Schmidt Arthur
Faculty of Medicine, Department of Medicine II, Medical Center, University of Freiburg, Freiburg, Germany.
Gastroenterology, Hepatology and Endocrinology, Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany.
Endosc Int Open. 2024 Aug 23;12(8):E989-E995. doi: 10.1055/a-2375-7568. eCollection 2024 Aug.
Endoscopic full-thickness resection (eFTR) allows treatment of "difficult to resect" lesions not amenable to conventional endoscopic methods. Efficacy and safety of the system have already been proven in numerous studies. Follow-up data on outcome of colorectal eFTR and management of recurrences are still rare. All patients undergoing colorectal eFTR at our institution with at least one endoscopic follow-up examination were retrospectively analyzed. The primary endpoint was the rate of recurrent or residual lesions (RRLs) and the secondary endpoint was the rate of late adverse events (AEs). We further aimed to identify risk factors for RRLs and to describe their management. Between November 2014 and 2021, 141 patients underwent eFTR at University Medical Center Freiburg. Ninety-one patients fulfilled the inclusion criteria. Indications for eFTR were non-lifting adenoma (n = 65), subepithelial tumors (n = 18) and early carcinoma (n = 8). The median follow-up period was 17 months (range, 2-86). The overall RRL rate was 9.9% (9/91). A significant proportion of RRLs (6/9, 66%) were detected late. All RRLs occurred in the group of non-lifting adenoma, corresponding to a RRL rate of 13.8% in this subgroup. Thirty-three percent (3/9) were initially treated by hybrid eFTR. Of the RRLs, 66.6% could were successfully treated endoscopically. On χ2 analysis, the hybrid eFTR technique ( = 0.006) was associated with a higher rate of RRL. No late AEs occurred. The rate of RRL after colorectal eFTR is low and the majority could be treated endoscopically. For non-lifting adenomas and early carcinomas, close follow-up is mandatory to detect late recurrence. Long-term outcomes after hybrid eFTR need further investigation.
内镜全层切除术(eFTR)可用于治疗无法用传统内镜方法切除的“难切除”病变。该系统的有效性和安全性已在众多研究中得到证实。关于结直肠eFTR结果及复发管理的随访数据仍然很少。对在我们机构接受结直肠eFTR且至少进行过一次内镜随访检查的所有患者进行了回顾性分析。主要终点是复发或残留病变(RRL)率,次要终点是晚期不良事件(AE)率。我们还旨在确定RRL的危险因素并描述其管理方法。2014年11月至2021年期间,141例患者在弗莱堡大学医学中心接受了eFTR。91例患者符合纳入标准。eFTR的适应证包括非抬举性腺瘤(n = 65)、上皮下肿瘤(n = 18)和早期癌(n = 8)。中位随访期为17个月(范围2 - 86个月)。总体RRL率为9.9%(9/91)。相当一部分RRL(6/9,66%)是晚期发现的。所有RRL均发生在非抬举性腺瘤组,该亚组的RRL率为13.8%。33%(3/9)最初采用混合eFTR治疗。在RRL中,66.6%可通过内镜成功治疗。经χ2分析,混合eFTR技术( = 0.006)与较高的RRL率相关。未发生晚期AE。结直肠eFTR后的RRL率较低,大多数可通过内镜治疗。对于非抬举性腺瘤和早期癌,必须密切随访以发现晚期复发。混合eFTR后的长期结果需要进一步研究。